Nykode Therapeutics ASVACBF -1.05%28 Quick Ratio is 12.66 as of Mar. 2026, which is 35% above its 10-year median of 9.37. GuruFocus rates VACBF with a GF Score™ of 28/100 and a GF Value™ of $0.76 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Nykode Therapeutics AS ranks better than 83.47% on this metric.
Nykode Therapeutics AS has a quick ratio of 12.66. It generally indicates good short-term financial strength.
The historical rank and industry rank for Nykode Therapeutics AS's Quick Ratio or its related term are showing as below:
VACBF'
s Quick Ratio Range Over the Past 10 Years
Min: 5.43 Med: 9.37 Max: 22
Current: 12.66
During the past 9 years, Nykode Therapeutics AS's highest Quick Ratio was 22.00. The lowest was 5.43. And the median was 9.37.
VACBF's Quick Ratio is ranked better than 83.47% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs VACBF: 12.66
Nykode Therapeutics AS (OTCPK:VACBF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Nykode Therapeutics AS Quick Ratio Related Terms
Nykode Therapeutics AS Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nykode Therapeutics AS's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nykode Therapeutics AS Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Nykode Therapeutics AS's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Nykode Therapeutics AS's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nykode Therapeutics AS (VACBF) has a Quick Ratio of 12.66 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Nykode Therapeutics AS and its competitors. This is 35% above median its historical median of 9.37. Over the past decade, Nykode Therapeutics AS's Quick Ratio has ranged from 5.43 to 22.00. According to the industry distribution chart, Nykode Therapeutics AS ranks #234 out of 1416 companies in the Biotechnology industry, placing it in the top 16.5%.
Is Nykode Therapeutics AS's Quick Ratio too high?
Nykode Therapeutics AS's current Quick Ratio of 12.66 is 35% above median its 10-year median of 9.37. Over the past 10 years, this metric has ranged from a low of 5.43 to a high of 22.00. The Biotechnology industry median Quick Ratio is 3.60. Nykode Therapeutics AS's value of 12.66 is 251.7% above this industry median. Based on the distribution chart, Nykode Therapeutics AS ranks #234 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nykode Therapeutics AS has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #234 out of 1416 companies for Quick Ratio. This places Nykode Therapeutics AS in the top 17% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Nykode Therapeutics AS's value of 12.66 is 251.7% above this benchmark. Historically, Nykode Therapeutics AS's own Quick Ratio has ranged from 5.43 to 22.00 over the past decade. While the company's 10-year median is 9.37 vs. the industry median of 3.60, Nykode Therapeutics AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nykode Therapeutics AS's current Quick Ratio of 12.66 is 251.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Nykode Therapeutics AS and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nykode Therapeutics AS's current Quick Ratio is 12.66, which is 35% above median its own 10-year median of 9.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (VACBF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.76, compared to a current price of $0.32 — trading 57.7% below its estimated fair value. The current Quick Ratio is 12.66, which is 35% above median its 10-year median of 9.37 and 251.7% above the Biotechnology industry median of 3.60. Nykode Therapeutics AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Nykode Therapeutics AS (VACBF), the current Quick Ratio is 12.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (VACBF) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of $0.32 is trading 57.7% below its estimated GF Value™ of $0.76.
GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.
Key valuation signals for VACBF:
Quick Ratio: 12.66 (35% above median its 10-year median of 9.37)
GF Value™: $0.76 vs. price of $0.32 (57.7% below fair value)
Industry Position: 251.7% above the Biotechnology median (#234 of 1416)
No single metric tells the full story. See the VACBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
28GF Score
Get the complete analysis for VACBF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VACBF has been successfully added to your 
